

1 **Title:** Measuring Baseline Health with Individual Health-Adjusted Life Expectancy (iHALE)

2

3 **Authors:** Kjell Arne Johansson (MD, PhD)<sup>1,2</sup>, Jan-Magnus Økland (MMath)<sup>1</sup>, Eirin Krüger  
4 Skaftun (MD)<sup>1</sup>, Gene Bukhman (MD, PhD)<sup>3</sup>, Ole Frithjof Norheim (MD, PhD)<sup>1,4</sup>, Matthew  
5 M. Coates (MPH)<sup>3</sup>, Øystein Ariansen Haaland (PhD)<sup>1</sup>

6

7 **Author affiliations:**

8 1. Bergen Centre for Ethics and Priority Setting (BCEPS), Department of Global Public  
9 Health and Primary Care, University of Bergen, Norway

10 2. Haukeland University Hospital, Department of Addiction Medicine, Bergen, Norway

11 3. Program in Global NCDs and Social Change, Harvard Medical School, Boston, USA

12 4. Harvard T. H. Chan School of Public Health, Harvard University, Boston, USA

13

14 **Corresponding author:**

15 Øystein Ariansen Haaland (PhD)

16 Mailing address: Department of Global Public Health and Primary Care, University of  
17 Bergen, PO Box 7804, 5020 Bergen, Norway

18 Email: [oystein.haaland@uib.no](mailto:oystein.haaland@uib.no)

19 Phone: +4755586124

20

21 **Funding:** Bill & Melinda Gates Foundation through the Disease Control Priorities Ethiopia  
22 (DCP-Ethiopia) project grant [OPP1162384] to the University of Bergen and Harvard T.H.  
23 Chan School of Public Health.

24

25

1 **ABSTRACT**

2

3 **Objectives:** At any point of time, a person’s baseline health is the number of healthy life  
4 years they are expected to experience during the course of their lifetime. In this article we  
5 propose an equity-relevant health metric, illness-specific individual Health Adjusted Life  
6 Expectancy (iHALE), that facilitates comparison of baseline health for individuals at the  
7 onset of different medical conditions, and allows for the assessment of which patient groups  
8 are worse off. A method for calculating iHALE is presented, and we use this method to rank  
9 four conditions in six countries according to several criteria of “worse off” as a proof of  
10 concept.

11

12 **Methods:** iHALE measures baseline health at an individual level for specific conditions, and  
13 consists of two components: past health (before disease onset) and future expected health  
14 (after disease onset). Four conditions (acute myeloid leukemia (AML), acute lymphoid  
15 leukemia (ALL), schizophrenia, and epilepsy) are analysed in six countries (Ethiopia, Haiti,  
16 China, Mexico, United States and Japan). Data for all countries and for all diseases in 2017  
17 were obtained from the Global Burden of Disease Study database. In order to assess who are  
18 the worse off, we focus on four measures: the proportion of affected individuals who are  
19 expected to attain less than 20 healthy life years (T20), the 25<sup>th</sup> and 75<sup>th</sup> percentiles of healthy  
20 life years for affected individuals (Q1 and Q3, respectively), and the average iHALE across  
21 all affected individuals.

22

23 **Results:** Even in settings where average iHALE is similar for two conditions, other measures  
24 may vary. One example is AML (average iHALE=58.7, T20=2.1, Q3-Q1=15.3) and ALL  
25 (57.7, T20=4.7, Q3-Q1=21.8) in the US. Many illnesses, such as epilepsy, are associated with

1 higher baseline health in high-income settings (average iHALE in Japan=64.3) than in low-  
2 income settings (average iHALE in Ethiopia=36.8).

3

4 **Conclusion:** iHALE allows for the estimation of the distribution of baseline health of all  
5 individuals in a population. Hence, baseline health can be incorporated as an equity  
6 consideration in setting priorities for health interventions.

## 1 INTRODUCTION

2 All health systems have budget constraints and limited resources. Methods for health  
3 economic evaluations, like cost-effectiveness analysis (CEA), are essential in health policy  
4 and are extensively used to rank health services by their expected efficiency [1]. However,  
5 few people endorse strict health maximisation [2], and fairness criteria may be included in  
6 such rankings [3, 4]. For example, one may give higher priority to interventions that target  
7 those with the most severe illnesses [5-7], especially in relation to decisions about the pricing  
8 and reimbursement of new medicines and devices [8, 9]. Policy makers in countries like  
9 Norway [10] and the Netherlands [11] have already started using severity measurement  
10 methods.

11  
12 In this paper, the terms “illness”, “disease” and “condition” are used interchangeably, and  
13 include all adverse medical conditions, such as injuries, syndromes, birth defects, and  
14 infections. The term “severity of illness” involves both substantial value disagreements and a  
15 wide range of interpretations [12, 13]. To sidestep misunderstandings, we use the concept of  
16 “baseline health at disease onset” rather than severity of illness. Three perspectives on how to  
17 measure baseline health dominate in the literature. One view considers current health [14],  
18 one considers health over future years [15], and one considers health over the lifetime [16-  
19 18]. In this paper we conform to the latter, and focus on how a particular illness is expected to  
20 affect the total lifetime health achieved by an individual before they die [18]. This includes  
21 both the past (before disease onset) and future (after disease onset). Clinical definitions of  
22 severity of illness often include urgency, but our definition of baseline health does not.  
23 Urgency pertains to the timing of treatment and how this influences the prognosis of a  
24 condition. Conditions with a low baseline health at onset, like multiple sclerosis in young  
25 patients, do not necessarily require urgent interventions.

1

2 The Global Burden of Disease (GBD) study provides critical summary measures of  
3 population health that are relevant when evaluating and comparing health systems [3]. These  
4 measures include disability-adjusted life years (DALY) and healthy life expectancy (HALE).  
5 DALYs are calculated for a set of diseases by summing the years of life lost (YLL) compared  
6 to a reference life expectancy and years lived with disability (YLD) in one particular year due  
7 to each disease [19]. For a particular condition and a particular year, YLL is the sum of all the  
8 years lost for the individuals who died from the condition during that year. The reference is  
9 the age-adjusted life expectancy (LE) from a life table derived from the mortality rates in the  
10 locations with the lowest age-specific mortality in the GBD study [20]. YLD, on the other  
11 hand, is the sum of the health loss due to the condition during the year across people living  
12 with the condition [21]. DALYs aggregated from YLLs and YLDs are a measure of overall  
13 population burden. A major limitation of these measures is that they do not capture how the  
14 condition affects the distribution of baseline health at onset across individuals in the  
15 population.

16

17 We propose a framework where this distribution is an integral part. A key component in this  
18 framework is the new metric individual Health Adjusted Life Expectancy (iHALE). In this  
19 paper, we present a method for calculating iHALE, and how to use iHALE to rank conditions  
20 according to baseline health at onset. We consider four conditions and six countries to  
21 illustrate how and why our framework is relevant for priority setting in health care and the  
22 measurement of population health.

## 1 **METHODS**

### 2 *Definition of iHALE*

3 iHALE measures lifetime health at an individual level for individuals with specific  
4 conditions, and consists of two components: past health and future expected health. We  
5 obviously do not know the actual time of death for people dying in the future, but we do have  
6 some knowledge about the expected distribution across individuals. Consider, for example,  
7 two people aged 30 (Ann) and 50 (Bob) who each get a disease. The prognosis for Ann is that  
8 she will certainly die within 20 years, but we do not know exactly when. The risk of dying is  
9 99% before her 50<sup>th</sup> birthday, but there is also a 1% chance that she will die in her 51<sup>st</sup> year.  
10 Bob, however, will certainly die before he is 51. For simplicity, we disregard health/disability  
11 adjustment for time with illness, and focus only on their age at death. In a lifetime health  
12 perspective, there is a 99% probability that Ann will die at a younger age than Bob will.  
13 Hence, Ann's baseline health is less than Bob's in terms of total length of life (past life plus  
14 expected future life), even though Bob's expected future life is shorter. This is true even if  
15 there is a 1% chance that Ann too will die in her 51<sup>st</sup> year. Health adjustment complicates  
16 matters, as we will discuss below, but the principles are the same. Of course, iHALE needs to  
17 go beyond hypothetical two-person cases to become a relevant health metric for priority  
18 setting in countries with millions of individuals and multiple diseases. iHALE enables  
19 comparison of both average baseline health and distribution of baseline health between  
20 individuals with different diseases. Methods for calculating the iHALE distribution within  
21 disease conditions are presented in the next sections.

22

### 23 *Data*

24 For illustrative purposes, we consider four conditions (acute myeloid leukemia (AML), acute  
25 lymphoid leukemia (ALL), schizophrenia, and epilepsy) in six countries (Ethiopia, Haiti,

1 China, Mexico, United States and Japan). The diseases have distinct properties that highlight  
2 certain characteristics of iHALE. The two leukemias are fatal, but the incidence of ALL peaks  
3 at both young and older age groups, whereas AML incidence peaks at old age groups only.  
4 Schizophrenia has large impact on disability over many years, and there are variations in both  
5 mortality and morbidity of epilepsy across countries. We consider the leukemias in a US  
6 setting, and then we compare schizophrenia and epilepsy across the six countries, representing  
7 low-, middle- and high-income settings with different age distributions, levels of health  
8 systems development, and access to healthcare among their populations. Data for all countries  
9 and for all diseases in 2017 are obtained from the freely available GBD cause of death  
10 database [20]. Table 1 describes variables available in the GBD database, and how they are  
11 used to derive other important variables.

12

13

[Table 1 here]

14

15 The GBD database gives the parameters from Table 1 in 5-year age groups to age 95. The  
16 under-5 age group is split into “less than one year old” (<1 group) and “1-4 years old”. To  
17 obtain single-year age estimates, we undertake the following procedures. For *pop*, we divide  
18 the population in the 4- and 5-year age groups evenly by single-year ages, and the terminal  
19 age group (95 plus) is divided equally in five parts from 95 to 99. For example, if 500 000  
20 individuals are in the 20-24 age group, we will assume that there are 100,000 20-year olds,  
21 100,000 21-year olds, and so on. For  $P_D$ ,  $I_D$ ,  $dw$ ,  $dw_D$ ,  $q(\text{age})$ , and  $M_D(\text{age})$ , we assume that  
22 the rates (or disability weights) are the same for each single-year age in the aggregate age  
23 groups. For example, if  $dw_D$  was 0.2 in the 20-24 age group, we assume that it was 0.2 for 20-  
24 year olds, 0.2 for 21-year olds, and so on.

25

1 *Part I: Estimating disease-specific individual life expectancy*

2 The individual life expectancy (iLE) of an individual is simply

3

4 
$$\text{iLE}(\text{age}) = \text{age} + \text{LY}^{\text{future}}(\text{age}), \quad (1)$$

5

6 where “age” is the age of the individual and  $\text{LY}^{\text{future}}$  is the number of life years each

7 individual has left to live at their respective age.  $\text{LY}^{\text{future}}$  is not known until the individual

8 actually dies, but its distribution can be estimated as follows. First, we define  $Y$ , the

9 maximum age in our lifetable, by setting the chance of surviving from age  $Y$  to  $Y+1$  to zero.

10 Then we calculate the number of people who are expected to die at different ages in the  $Y$

11 years to come. This can be done using an upper diagonal  $(Y + 1) \times (Y + 1)$  matrix,

12

13

14 
$$\mathbb{N}_{\text{iLE}} = \begin{bmatrix} N_{0,0} & N_{0,1} & N_{0,2} & \cdots & N_{0,Y} \\ - & N_{1,1} & N_{1,2} & \cdots & N_{1,Y} \\ - & - & N_{2,2} & \cdots & N_{2,Y} \\ - & - & - & \ddots & \vdots \\ - & - & - & \cdots & N_{Y,Y} \end{bmatrix}. \quad (2)$$

15

16 In each element of  $\mathbb{N}_{\text{iLE}}$ ,  $N_{c,d}$ , the  $c$  denotes the current age and the  $d$  denotes the age at death.

17 For example,  $N_{3,12}$  is the number of today’s 3-year-olds who will die at age 12. Each  $N_{c,d}$  is

18 calculated using standard lifetable methodology [22], based on the assumption that  $q(\text{age})$

19 remains the same in the future. In other words,  $\{N_{c,0}, N_{c,1}, \dots, N_{c,Y}\}$  is the distribution of age at

20 death for an individual with current age  $c$ . We see that summing the rows,  $\sum_{d=0}^Y N_{c,d}$ , yields

21 the population age structure (pop). Further, summing the columns,  $\sum_{c=0}^Y N_{c,d}$ , gives the

22 number of people that we expect to die at age  $d$ . That is, the number of people for which

23  $\text{iLE} = d$ . The sum  $\sum_c \sum_d N_{c,d}$  is the total current number of people at all ages. In our



1 calculations, we use  $Y=99$ . Note that it follows from the assumption of a static  $q(\text{age})$  that  
2 average  $LY^{\text{future}}$  is the same as LE. From (1) we see that iLE is dominated by  $LY^{\text{future}}$  for  
3 young children, and by age for very old people.

4

5 Before we break the analysis into diseases, we start by analyzing total figures for one country,  
6 as this is familiar for most readers and perhaps more intuitive. Figure 1 shows the distribution  
7 of iLE for all age groups in the total population of the United States in 2017. In the left panel,  
8 individuals alive in 2017 are ranked by their current age, and the right panel ranks them by  
9 iLE. Now we can see that around 22 million people (7%) in the US have  $iLE < 60$  years. As  
10 expected, the proportion is much higher in Ethiopia (16%) and Haiti (20%). Note that by  
11 simply focusing on LE, we would know nothing about such distributional characteristics.

12

13 [Figure 1 here]

14

15 For individuals who get a disease,  $D$ , at a particular age, (1) becomes

16

$$17 \quad iLE_D(\text{age}) = \text{age} + LY_D^{\text{future}}(\text{age}) . \quad (4)$$

18

19  $LY_D^{\text{future}}$  is calculated similarly to  $LY^{\text{future}}$ . Instead of  $\text{pop}(\text{age})$ , we use  $I_D(\text{age}) \times \text{pop}(\text{age})$

20 (Table 1), and instead of mortality rates for the general population, we use those of

21 individuals with condition  $D$ ,  $q_D$  (Table 1). For diseases with very high mortality,  $LY_D^{\text{future}}$

22 will be small for all ages, and  $iLE_D$  will therefore to a large extent depend on age alone. If the

23 excess mortality is low, the situation resembles that of (1).

24

1 Figure 2 shows the estimated iLE distribution among the 10,600 people with incident cases of  
2 acute myeloid leukemia (AML) and 1,950 people with incident cases of acute lymphoid  
3 leukemia (ALL) in the United States in 2017. The LE was 67.9 for AML and 67.6 for ALL.  
4 However, as the figure shows, the mean age of onset in the United States in 2017 was 62.5 for  
5 AML and 45.6 for ALL, and mean  $LY_{AML}^{future}$  was 5.4 years, whereas  $LY_{ALL}^{future}$  was 22 years.  
6 Once again, we see that important information about baseline health is lost when focusing on  
7 LE only.

8

9 [Figure 2 here]

10

## 11 *Part II. Adjust for morbidity*

12 Non-fatal morbidities should also be taken into account when assessing baseline health at  
13 disease onset, so that one can compare across fatal and non-fatal diseases with different  
14 impacts on health loss. This includes estimating health adjusted age (HAA) and future health  
15 adjusted life years ( $HALY^{future}$ ). Expanding on (4), we get

16

$$17 \quad iHALE_D(\text{age}) = HAA^{past}(\text{age}) + HALY_D^{future}(\text{age}), \quad (5)$$

18

19 In this section we will explain how to estimate  $HAA^{past}$  and  $HALY_D^{future}$  using the background  
20 disability,  $dw$ , and the excess disease-specific disability,  $dw_D$  (Table 1).

21

22 Figure 3 outlines the conceptual structure of the iHALE method, where both past and future  
23 health is summed for each individual with one of the four diseases AML, ALL, epilepsy and  
24 schizophrenia.

25

1 [Figure 3 here]

2

3 HAA<sup>past</sup> is calculated as follows,

4

5 
$$\text{HAA}^{\text{past}}(c) = \sum_{i=0}^{c-1} (1 - dw(i)), \quad (6)$$

6

7 where,  $c$  is current age and  $dw(i)$  is the background disability from age “ $i$ ” to “ $i+1$ ” (Table 1).

8 We assume that conditions are independent and that past  $dw$  are the same regardless of

9 current disease status.

10

11 To account for future non-fatal health loss caused by a disease,  $D$ , we use disease specific

12 excess disability,  $dw_D$ , and mortality,  $q_D$ , as calculated in Table 1. However, mortality risk is

13 returned from  $q_D$  to  $q$  after a period of increased mortality (PIM), and morbidity returns from

14  $dw_D$  to  $dw$  after a period of increased disability (PID) (Table 1 expands on PIM and PID).

15

16 In Figure 3 we see from the AML examples how two different persons may fare under the

17 same PIM and PID. Person 1 survives long enough that both mortality and morbidity return to

18 those of the background population, and then dies at age 63 from a different cause, whereas

19 Person 2 dies during the PIM.

20

21 Future health adjusted life years, as a function of current age and age at death, is

22

23 
$$\text{HALY}_D^{\text{future}}(c, d) = \begin{cases} 0.5 \times (1 - dw_D^{\text{PID}}(d)), & c = d \\ (c + 0.5) - (0.5 \times dw_D^{\text{PID}}(d) + \sum_{i=c}^{d-1} dw_D^{\text{PID}}(i)), & c < d \\ -, & c > d \end{cases} \quad (7)$$

24

1 where  $c$  is current age and  $d$  is age at death. As in (6),  $dw_D^{\text{PID}}(i)$  is the disability weight from  
 2 age “ $i$ ” to “ $i+1$ ”. However, because we estimate future health loss, the disability weight must  
 3 be adjusted during PID. This means that the disability increased for a period of PID years  
 4 after onset before returning to that of the general population (Table 1).

5

6 We next set out to estimate the iHALE distribution in a population. This is done in several  
 7 steps. First, we create one matrix for past health, and one for future health. The matrix for past  
 8 health is

9

$$10 \quad \mathbb{H}^{\text{past}} = \begin{bmatrix} 0 & 0 & \dots & \dots & 0 \\ - & \text{HAA}^{\text{past}}(1) & \dots & \dots & \text{HAA}^{\text{past}}(1) \\ - & - & \text{HAA}^{\text{past}}(2) & \dots & \text{HAA}^{\text{past}}(2) \\ - & - & - & \ddots & \vdots \\ - & - & - & - & \text{HAA}^{\text{past}}(Y) \end{bmatrix}, \quad (8)$$

11

12 where  $\text{HAA}^{\text{past}}$  is from (6). Because the row number represents current age, we see that the  
 13 elements are the same within each row. In other words, your past health only depends on your  
 14 current age, and not your future age at death (column number).

15

16 In the matrix for future health, we need to account for both current age and age at death.

17 Using  $\text{HALY}_D^{\text{future}}$  from (7), we get

18

$$19 \quad \mathbb{H}_D^{\text{future}} = \begin{bmatrix} \text{HALY}_D^{\text{future}}(0,0) & \text{HALY}_D^{\text{future}}(0,1) & \dots & \text{HALY}_D^{\text{future}}(0,Y) \\ - & \text{HALY}_D^{\text{future}}(1,1) & \dots & \text{HALY}_D^{\text{future}}(1,Y) \\ - & - & \ddots & \vdots \\ - & - & - & \text{HALY}_D^{\text{future}}(Y,Y) \end{bmatrix}. \quad (9)$$

20

21 Adding past and future health yields

1

2

$$\mathbb{H}_D^{\text{iHALE}} = \mathbb{H}^{\text{past}} + \mathbb{H}_D^{\text{future}} . \quad (10)$$

3

4

In  $\mathbb{H}_D^{\text{iHALE}}$ , row number  $c$  gives iHALE for individuals who are  $c$  years old, whereas column

5

number  $d$  gives the iHALE for individuals who will die at age  $d$ . As opposed to the discrete

6

iLE, iHALE is continuous. For example, one individual who dies at age 80 may have an

7

iHALE equal to 67.3 healthy years, whereas another could have achieved 67.4 or 67.5.

8

Because we do not have access to data on individuals, every individual with the same

9

condition and the same age of onset is assumed to have the same iHALE distribution. In  $\mathbb{N}_{\text{iLE}}$

10

from (2), we obtained these distributions by considering the rows. This information is not

11

available in  $\mathbb{H}_D^{\text{iHALE}}$ , but we may create a new matrix,  $\mathbb{N}_{\text{iLE}}^{\text{PIM}}$ , where the elements correspond to

12

those of  $\mathbb{N}_{\text{iLE}}$ , but are calculated using  $q_D^{\text{PIM}}$  instead of  $q$  (Table 1).

13

Pairing all elements in  $\mathbb{N}_{\text{iLE}}^{\text{PIM}}$  with the corresponding element in  $\mathbb{H}_D^{\text{iHALE}}$  yields the iHALE

14

distribution for all values of  $c$  and  $d$  for the disease  $D$ .

15

16

In  $\mathbb{N}_{\text{iLE}}^{\text{PIM}}$  we use incidence to identify those who get the disease  $D$  each year, which is

17

especially useful for life-long conditions. See Figure A1 (Appendix) for details on incidence

18

assumptions that are being used in iHALE calculations for AML and ALL in the US.

19

20

[Figure 4 here]

21

22

Figure 4 shows that even though average iHALE is similar for AML (58.7) and ALL (57.7),

23

the distribution across individuals is different. For example, in the US we expect 4.7% of

24

individuals with ALL to have iHALE < 20 (T20), compared with only 2.1% for individuals

25

with AML. Hence, considering risk of a low baseline health, individuals with ALL would be

1 worse off. Still, the 75<sup>th</sup> percentile (Q3) of iHALE for individuals with ALL (71.3) was higher  
2 than in people with AML (67.9), so with respect to chance of a high baseline health  
3 individuals with AML would be the worse off. Again, this highlights the need for  
4 distributional concerns in policy making.

5

6 *Data availability statement*

7 The data used to create the tables and figures in this paper can be accessed without restrictions  
8 at <https://doi.org/10.5281/zenodo.3258330>.

1     **RESULTS**

2     Table 2 shows average iHALE, T20, Q1 and Q3 for ALL, AML, schizophrenia and epilepsy  
3     in six countries (see Appendix Table A4 for 200 NCDI conditions). Rank orders of the four  
4     conditions varied both between countries and according to measure of who is worse off.

5

6                                                             [Table 2 here]

7

8     The iHALE distribution for schizophrenia was similar across the six settings, although Japan  
9     stands out in a positive manner. The difference in average iHALE for schizophrenia between  
10    the US and Japan was larger than the difference between the US and Ethiopia (Haiti 40.7,  
11    Ethiopia 41.1, China 45.7, Mexico 44.4, US 43.5, Japan 48.6). The same applied to the  
12    quartiles. T20, the proportion of people with iHALE <20, was low across countries for  
13    schizophrenia, which is reasonable, as schizophrenia rarely manifests in childhood.  
14    Variability in average iHALE for epilepsy between countries was high (Ethiopia 36.8, Haiti  
15    39.5, Mexico 53.5, China 56.6, US 58.8, Japan 64.3). In addition, there is much more unequal  
16    iHALE distribution for epilepsy in countries with low average iHALE (difference between  
17    quartiles (Q3-Q1) was 19.9 in Ethiopia, 17.9 in Haiti, 15.2 in China, 14.9 in Mexico, 13.3 in  
18    Japan, and 13.2 in the US). Further, only 0.6% of the Japanese had iHALE under 20, but the  
19    number was 14.0% among Ethiopians and 8.4% among Haitians.

## 1 **DISCUSSION**

2 According to fairness concerns, limited health care resources should be allocated to  
3 interventions that benefit the worse off in society [5-7, 18]. In this paper, we present a  
4 quantitative method for identifying the worse off by estimating the distribution of lifetime  
5 health across individuals in the same disease category. We show how two conditions, ALL  
6 and AML, with similar LEs and average iHALEs have substantially different distributions of  
7 iHALE. In addition, we show how iHALE varies across countries, and demonstrate how the  
8 iHALE distribution captures different aspects of the fact that diseases are typically more  
9 severe in low-income than in high-income countries. Our new framework important for  
10 priority setting because it can be used to assign extra value to health gains from interventions  
11 targeting the worse off. The relevance of iHALE is particularly good for preventive  
12 interventions for a disease where you are likely to capture benefits across a range of ages (for  
13 example treating strep throat in school children to prevent rheumatic heart disease).

14

15 Sullivan, in 1971, suggested how morbidity adjustment could be done for LE to get HALE by  
16 modifying the standard life table model to estimate the expected duration of a condition by  
17 exposing a birth cohort of a disease specific mortality and disability rate over a lifetime [22].  
18 Sullivan's method estimates average expected years of healthy life rather than the distribution  
19 of iHALE between individuals as done in this paper.

20

21 In this article we present iHALE as an achievement measure, but it may be more intuitive to  
22 present baseline health at disease onset as a shortfall from what individuals could potentially  
23 achieve. iHALE could be converted to an individual gap-measure (e.g. iDALY) by using the  
24 YLL method applied in GBD. Shortfall in life years could be calculated for each individual at  
25 disease onset by using the lowest mortality by age in the world as a reference. Shortfall in



1 disabilities could use the lowest YLD rates across countries as a reference for disability  
2 shortfall. However, disease shortfall measures are beyond the scope of this paper.  
3  
4 PIM and PID, as presented in this paper, have some limitations. They could be different for  
5 the same condition across settings, as would be the case for conditions, like HIV, that can be  
6 treated or controlled more effectively in some countries than in others. Part of these  
7 differences should be captured in the excess mortality differences between countries in our  
8 current analysis, but the durations of the periods are also likely to vary. Additionally, PIM and  
9 PID do not capture the nature of conditions where mortality and morbidity have complicated  
10 temporal patterns. For example, the peak increase in mortality risk for HIV patients is about a  
11 decade after onset. At a conceptual level, these obstacles are easy to handle. One simply must  
12 estimate PIM and PID for all conditions under consideration in all relevant settings. However,  
13 the empirical task of getting precise PIM and PID estimates is not trivial.

14

15 Understanding the underlying reasons for differences in the distribution of iHALE can have  
16 policy implications. Observed differences in the distribution of iHALE between countries can  
17 originate from a number of reasons. It is important to note that as a measure of lifetime health  
18 among people with a specific condition, iHALE is influenced by mortality risk and morbidity  
19 from other causes, as well as by the age at which the disease occurs. Thus, variation in iHALE  
20 could be caused from differences in demography and epidemiology at the country level, or  
21 from variations in access to health care that underlie differences in disease-specific morbidity  
22 or mortality rates. The relative contribution of each of these differences to the overall  
23 difference in iHALE between countries depends on which countries are being compared. How  
24 to quantify the role of each factor is discussed further in Appendix (Figure A2).

25

1 To measure the true disease-specific baseline health distribution, the past health would be  
2 calculated using observed past disability for individuals. The data available for our  
3 calculations were limited in several ways. There was no individual-level morbidity and  
4 mortality information, so we used population averages. This meant that we were unable to  
5 account for correlation between illnesses. For example, people who die of a car accident at  
6 age 45 may be different on average from those who die of a myocardial infarction at age 45  
7 regarding lifestyle (smoking, exercise, diet) and biology (metabolism, genetics), which could  
8 affect the risk of other morbidities. As a result, our estimates of iHALE may be high  
9 (overestimate baseline health) for illnesses that are often experienced with comorbidities  
10 because they do not capture the higher burden from the associated illnesses. Conversely, our  
11 estimates of iHALE may be low (underestimate baseline health) for illnesses that have few  
12 comorbidities. These limitations are especially evident in mental health conditions. The GBD  
13 estimates do not attribute any mortality to mental health disorders; however, we know that  
14 patients with mental health disorders have higher mortality risk compared to the general  
15 population [23-25]. Our schizophrenia iHALE results are additionally limited by distributions  
16 of disability weights that do not vary along with treatment availability across countries [26].  
17 The limited time series available from the GBD meant that we did not have complete  
18 historical average disability rates. For consistency, we used age-specific rates of disability for  
19 the calculations of past health; however, health achievement in a real population would use  
20 historical disability information if available.

## 1 **CONCLUSION**

2 Increasing availability of demographic and epidemiologic data creates opportunities for  
3 quantifying the baseline health at disease onset to guide priority setting in health care. Policy  
4 makers, supported by the ethical literature, are concerned about giving higher priority to the  
5 worse off. However, the impact of such fairness concerns to health policy does not match the  
6 impact cost-effectiveness analysis has had on policy the last decades. Data availability and  
7 lack of rigorous methods for quantifying the baseline health at disease onset are likely  
8 contributing factors to the negligence of the worse off in de facto health care priority setting.  
9 Here we have presented a method for calculating iHALE and illustrate with examples how  
10 and why a metric that is sensitive to distribution is relevant for priority setting in health care  
11 and the measurement of population health. We lay the foundations for undertaking detailed  
12 calculations of disease-specific iHALE in multiple countries.

1 **LIST OF ABBREVIATIONS:**

- 2 individual Health Adjusted Life Expectancy (iHALE), individual life expectancy (iLE);
- 3 Period of Increased Mortality (PIM); Period of Increased Disability (PID); health adjusted age
- 4 (HAA); cost-effectiveness analysis (CEA); Global Burden of Diseases (GBD); disability-
- 5 adjusted life-years (DALY); healthy life years (HALY); years of life lost (YLL); years lived
- 6 with disability (YLD); acute myeloid leukemia (AML); acute lymphoid leukemia (ALL)

## 1 REFERENCES

- 2 1. Greenberg, D. and P.J. Neumann, *Cost-Effectiveness Analysis Expands its Reach Worldwide*. Value Health Reg Issues, 2016. **10**: p. 101-102.
- 3 2. Cookson, R., et al., *Using Cost-Effectiveness Analysis to Address Health Equity Concerns*. Value Health, 2017. **20**(2): p. 206-212.
- 4 3. Ottersen, T., et al., *Making fair choices on the path to universal health coverage*. Bull World Health Organ, 2014. **92**(6): p. 389.
- 5 4. World Health Organization, *Making fair choices on the path to universal health coverage*. 2014, World Health Organization: Geneva.
- 6 5. Norheim, O.F., et al., *Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis*. Cost Eff Resour Alloc, 2014. **12**: p. 18.
- 7 6. Johri, M. and O.F. Norheim, *Can cost-effectiveness analysis integrate concerns for equity? Systematic review*. Int J Technol Assess Health Care, 2012. **28**(2): p. 125-32.
- 8 7. Nord, E. and R. Johansen, *Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY*. Health Policy, 2014. **116**(2-3): p. 281-8.
- 9 8. Mirelman, A., et al., *Decision-making criteria among national policymakers in five countries: a discrete choice experiment eliciting relative preferences for equity and efficiency*. Value Health, 2012. **15**(3): p. 534-9.
- 10 9. Tanios, N., et al., *Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers*. Int J Technol Assess Health Care, 2013. **29**(4): p. 456-65.
- 11 10. Ottersen, T., et al., *A new proposal for priority setting in Norway: Open and fair*. Health Policy, 2016. **120**(3): p. 246-51.
- 12 11. van de Wetering, E.J., et al., *Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall*. Eur J Health Econ, 2013. **14**(1): p. 107-15.
- 13 12. Barra, M., et al., *Severity as a Priority Setting Criterion: Setting a Challenging Research Agenda*. Health Care Anal, 2019.
- 14 13. Olsen JA., *Beyond cost-effectiveness: priority setting*, in *Principles in Health Economics and Policy*, Olsen JA., Editor. 2017, Oxford Scholarship Online.
- 15 14. Nord, E., *Cost-value analysis in health care: making sense out of QALYs*. Cambridge studies in philosophy and public policy. 1999, Cambridge: Cambridge University Press. XXIII, 157 s.
- 16 15. Scanlon, T.M., *Kamm on the disvalue of death*. J Med Ethics, 2015. **41**(6): p. 490.
- 17 16. Adler, M., *Well-Being and Fair Distribution: Beyond Cost-Benefit Analysis*. 2011: Oxford University Press.
- 18 17. Otsuka, M. and A. Voorhoeve, *Why It Matters That Some Are Worse Off Than Others: An Argument against the Priority View*. PHILOSOPHY & PUBLIC AFFAIRS, 2009. **37**(2): p. 171-199.
- 19 18. Ottersen, T., *Lifetime QALY prioritarianism in priority setting*. J Med Ethics, 2013. **39**(3): p. 175-80.
- 20 19. Institute for Health Metrics and Evaluation and collaborators, *Global Burden of Disease study (2017, 2016, 2015, 2013 and 2010)*. Lancet, 2018, 2017, 2016, 2014, 2012.
- 21 20. GBD Causes of Death Collaborators, *Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017*. Lancet, 2018. **392**(10159): p. 1736-1788.
- 22 21. Schroeder, S.A., *Incidence, prevalence, and hybrid approaches to calculating disability-adjusted life years*. Popul Health Metr, 2012. **10**(1): p. 19.
- 23 22. Sullivan, D.F., *A single index of mortality and morbidity*. HSMHA Health Rep, 1971. **86**(4): p. 347-54.

- 1 23. Thornicroft, G., *Physical health disparities and mental illness: the scandal of premature*
- 2 *mortality*. Br J Psychiatry, 2011. **199**(6): p. 441-2.
- 3 24. Lawrence, D., S. Kisely, and J. Pais, *The epidemiology of excess mortality in people with*
- 4 *mental illness*. Can J Psychiatry, 2010. **55**(12): p. 752-60.
- 5 25. Vigo, D., G. Thornicroft, and R. Atun, *Estimating the true global burden of mental illness*.
- 6 *Lancet Psychiatry*, 2016. **3**(2): p. 171-8.
- 7 26. Burstein, R., et al., *Estimating distributions of health state severity for the global burden of*
- 8 *disease study*. Popul Health Metr, 2015. **13**: p. 31.

1 **TABLES**

2

3 **Table 1:** Description of data and variables used to calculate individual Health Adjusted Life

4 Expectancy (iHALE), the GBD 2017 study [3] is source for all calculations.

Variable	Description
PIM	<p><i>Period of increased mortality.</i></p> <p>From expert opinions.</p> <p>Number of years with increased mortality after disease onset. The rate at which mortality declines in the PIM is specific for each condition.</p> <p>For simplicity, PIM=100 for chronic diseases. We use PIM=5 for the leukemias.</p>
PID	<p><i>Period of increased disability.</i></p> <p>From expert opinions.</p> <p>Number of years with increased disability after disease onset. The rate at which disability declines in the PID is specific for each condition.</p> <p>For simplicity, PID=100 for chronic diseases. We use PID=5 for the leukemias.</p>
pop	<p><i>Population size, per 5-year age interval.</i></p> <p>From GBD 2017.</p> <p>Transformed to 1-year age intervals by distributing individuals evenly across the five years.</p>
$P_D$	<p><i>Prevalence (per population) of disease per 5-year age interval.</i></p> <p>From GBD 2017.</p> <p>Assumed to be the same in all 1-year intervals.</p>
$I_D$	<p><i>Incidence (per population) of disease per 5-year age interval.</i></p> <p>From GBD 2017.</p> <p>Assumed to be the same in all 1-year intervals.</p>
$M_D$	<p><i>Disease specific probability of death per 5-year age interval, for total population.</i></p>

	<p>From GBD 2017.</p> <p>Assumed to be the same in all 1-year intervals.</p>
q	<p>All cause probability of death per 5-year age interval, for total population (background mortality). From GBD 2017.</p> $q = M_{\text{All causes}}$ <p>Assumed to be the same in all 1-year intervals.</p>
YLD <sub>D</sub>	<p>Years Lived with Disability of disease per 5-year age interval.</p> <p>From GBD 2017.</p> <p>Assumed to be the same in all 1-year intervals.</p>
<b>Derived</b>	
em <sub>D</sub>	<p>Excess mortality due to disease (case fatality rate). These are not given directly in GBD, but can be calculated using</p> $em_D(\text{age}) = \frac{M_D(\text{age})}{P_D(\text{age})} .$ <p>This is the extra risk of dying for individuals with disease that is caused directly by the disease itself. Note that this is different from M<sub>D</sub>, which is the risk of dying from a particular disease for any individual in the population.</p>
q <sub>D</sub>	<p>Probability of death due to disease and background mortality. These are not given directly in GBD, but can be calculated using</p> $q_D(\text{age}) = q(\text{age}) - M_D(\text{age}) + em_D(\text{age}) .$ <p>Substituting em<sub>D</sub> into q<sub>D</sub> yields</p> $q_D(\text{age}) = q(\text{age}) + M_D(\text{age}) \left( \frac{1}{P_D(\text{age})} - 1 \right) .$



	<p>We can see that if <math>P_D=1</math>, meaning that all individuals in the population have a disease, <math>q_D</math> simply becomes <math>q</math>. This is also the case if there is no mortality from disease, so that <math>M_D=0</math>.</p>
$q_D^{PIM}$	<p>During the period of increased probability of death due to disease, <math>q_D</math> is used for PIM years. After the period, <math>q_D</math> returns to <math>q</math>.</p>
$dw$	<p>Background disability weight from the population overall (0 is no disability and 1 is death).</p> $dw = \frac{YLD_{All\ causes}}{100000}$
$dw_D$	<p>Average disability weight due to the disease of interest (0 is no disability and 1 is death).</p> $dw_D(\text{age}) = \frac{YLD_D(\text{age})}{P_D(\text{age})}$
$dw_D^{PID}$	<p>During the period of increased disability, the disability weight is</p> $dw_D^{PID} = 1 - \left( 1 - \frac{\frac{YLD_{All\ causes}}{100000} - \frac{YLD_D}{100000}}{1 - \frac{YLD_D}{100000}} \right) (1 - dw_D)$ <p>After the period, <math>dw</math> returns to that of the background population (<math>dw</math>).</p>

- 1 **Table 2:** Average individual Health Adjusted Life Expectancy (iHALE), T20, Q1 and Q3 for four
- 2 conditions in six countries, results from 200 NCDI conditions can be found in the Appendix Table A4
- 3 (the GBD 2017 study [3] is source for all calculations).

		Acute lymphoid leukemia	Acute myeloid leukemia	Epilepsy	Schizophrenia
Ethiopia	Average iHALE	33.0	30.8	36.8	41.1
	T20 (%)	47.5	41.2	14.1	0.5
	Q1	7.8	7.0	26.3	35.6
	Q3	61.0	51.7	46.2	46.0
Haiti	Average iHALE	33.4	33.5	39.5	40.7
	T20 (%)	44.4	32.0	8.3	0.5
	Q1	9.5	13.5	30.5	35.3
	Q3	58.3	51.0	48.4	45.5
China	Average iHALE	57.5	46.5	56.6	45.7
	T20 (%)	5.1	15.2	1.8	0.1
	Q1	47.4	31.6	50.4	39.3
	Q3	71.6	62.8	65.6	51.4
Mexico	Average iHALE	44.5	39.4	53.5	44.4
	T20 (%)	23.7	23.0	2.0	0.2
	Q1	20.4	21.4	46.8	38.7
	Q3	66.8	56.6	61.7	49.7
US	Average iHALE	57.7	58.7	58.8	43.5
	T20 (%)	4.7	2.1	0.7	0.2
	Q1	49.5	52.6	53.3	38.2
	Q3	71.3	67.9	66.5	47.9
Japan	Average iHALE	66.0	62.8	64.3	48.6
	T20 (%)	1.5	1.6	0.6	0.0
	Q1	60.7	57.3	59.1	42.1
	Q3	76.6	71.6	72.4	54.4

4 T20: Proportion of individuals with disease who attain iHALE > 20.

5 Q1: Attained iHALE for the individual at the 25<sup>th</sup> percentile

6 Q3: Attained iHALE for the individual at the 75<sup>th</sup> percentile

7

1 **FIGURES**

2 **Figure 1:** Distribution of individual life expectancy (iLE) for the total US population (2017).

3 Left panel: Distribution by age. On the x-axis, -100 corresponds to the year 1917, and +100  
4 corresponds to the year 2117. Years lived before 2017 are observed, whereas years lived after  
5 2017 are expected.

6 Right panel: Distribution by iLE.

7

8 **Figure 2:** Individual life expectancy (iLE) for individuals who got leukemia in the US in  
9 2017, sorted according to age at onset. Left panel: Distribution for acute myeloid leukemia  
10 (AML). Right panel: Distribution for acute lymphoid leukemia (ALL).

11

12 **Figure 3:** Outline of the conceptual structure of the individual Health Adjusted Life  
13 Expectancy (iHALE) method, where we calculate the sum of past health and expected future  
14 health for five individuals with different diseases (AML, ALL, epilepsy and schizophrenia).  
15 For a disease D, the dashed black line is background mortality, and the blue line is  
16 background mortality added to the excess risk of death caused by D. The orange area is  
17 background health loss due to disability ( $dw$ ), and the red area is health loss caused by D  
18 ( $dw_D$ ). The grey area is  $iHALE_D$ . The sum of the grey, orange and red areas constitute iLE.  
19 The top solid black line gives a period after the onset of D when the person had a period of  
20 increased mortality (PIM). The bottom line gives a similar period of increased disability  
21 (PID).

22

23 **Figure 4:** Distribution of individual Healthy Adjusted Life Expectancy (iHALE) for AML  
24 and ALL in the United States in 2017.

25

1 **Appendix**

2

3 **A1 Incidence**

4

5 Figure A1 shows details on incidence assumption that is being used in iHALE calculations.

6

7 [Figure A1 here]

8

9 **Figure A1:** Incidence rates (top) and incidence (bottom) across age groups for AML and  
10 ALL in the United States (2017) [1].

## 1 **A2 Decomposition**

2 To illustrate how differences in demography, epidemiology, and disease specific mortality  
3 and morbidity led to differences in average iHALE between Japan and Ethiopia as exemplars,  
4 we took an approach that parallels methods described by Das Gupta [2], creating estimates  
5 using the 64 possible scenarios of the two values for the 6 input factors. For each factor, there  
6 are then 32 pairs of scenarios in which all five other factors remain constant but the factor in  
7 question takes on either Japan or Ethiopia's value. To calculate the effect of each factor on the  
8 overall iHALE difference between Ethiopia and Japan, we took the average of the difference  
9 in iHALE between these 32 sets of paired scenarios. Essentially, this is the average effect of  
10 varying that one factor with every possible combination of other factors. Figure A2 shows the  
11 results of this decomposition. As expected, the younger age structure in Ethiopia and the  
12 higher overall mortality contributes substantially to differences in iHALE. However, we also  
13 see that disease-specific mortality differences play a large role for epilepsy, leading to a much  
14 lower iHALE in Ethiopia. The disease-specific disability plays a very small role for  
15 schizophrenia, as discussed in the main text, because of a lack of variation in the distribution  
16 of severity across countries in the input data from the GBD data (see A3). Surprisingly, the  
17 age distribution of incidence contributes to higher iHALE in Ethiopia, a function of the age  
18 distribution of incidence rates from GBD, which tend to be higher at older ages and lower at  
19 younger ages in Ethiopia.

20  
21 [Figure A2 here]

22  
23 **Fig A2:** Difference in iHALE between Japan and Ethiopia for 4 diseases (Acute lymphoid  
24 leukemia, Acute myeloid leukemia, Epilepsy and schizophrenia), decomposed into factors  
25 driving differences.

1 **A3 Age-standardized average disability weight**

2 Mental disorders like major depressive disorder (MDD), bipolar disorder, and schizophrenia  
3 show almost no difference in age-standardized average disability weight between high income  
4 and low income countries in GBD, despite higher treatment rates in high income settings. We  
5 might expect the distribution of severity to be more severe in low income settings where  
6 treatment is less available. Differences in iHALE between high and low income settings,  
7 particularly for nonfatal conditions like mental health disorders, are limited by these estimated  
8 severities in GBD. Note the much larger difference in average disability weight for epilepsy.

9

10 [Figure A3 here]

11

12 **Figure A3:** Age-standardized average disability weight (YLDs/Prevalence) in High Income  
13 versus Low Income countries by World Bank income groups.

14 MDD=Major depressive disorder

## A4 iHALE for 200 diseases in 6 countries

Table A1 shows results for iHALE for 200 NCDI conditions for Ethiopia, Haiti, China, Mexico, US and Japan.

**Table A1:** iHALE for 200 NCDI conditions for Ethiopia, Haiti, China, Mexico, US and Japan (T20 is the % with iHALE<20, Q1 is quartile 1 and Q3 is quartile 3).

	Ethiopia				Haiti				China				Mexico				US				Japan			
	Average iHALE	T20 (%)	Q1	Q3	Average iHALE	T20 (%)	Q1	Q3	Average iHALE	T20 (%)	Q1	Q3	Average iHALE	T20 (%)	Q1	Q3	Average iHALE	T20 (%)	Q1	Q3	Average iHALE	T20 (%)	Q1	Q3
Acne vulgaris	63.4	0.6	57.5	71.7	60.1	0.7	53.4	69.0	69.0	0.1	63.6	75.5	67.4	0.4	61.5	75.7	67.2	0.2	62.1	74.6	73.2	0.1	69.4	79.3
Acute glomerulonephritis	61.0	5.0	55.9	71.0	56.4	7.0	49.4	68.3	58.4	3.1	47.7	71.3	67.1	1.5	61.6	75.8	69.2	0.1	65.1	75.2	74.4	0.1	71.0	79.4
Acute lymphoid leukemia	33.0	47.5	7.8	61.0	33.4	44.4	9.5	58.3	57.5	5.1	47.4	71.6	44.5	23.7	20.4	66.8	57.7	4.7	49.5	71.3	66.0	1.5	60.7	76.6
Acute myeloid leukemia	30.8	41.2	7.0	51.7	33.5	32.0	13.5	51.0	46.5	15.2	31.6	62.8	39.4	23.0	21.4	56.6	58.7	2.1	52.6	67.9	62.8	1.6	57.3	71.6
Adverse effects of medical treatment	58.8	7.2	54.2	71.0	54.4	8.5	47.6	67.5	70.6	0.2	65.9	75.5	66.9	2.2	62.3	75.7	70.5	0.0	66.4	75.2	74.3	0.2	70.9	79.3
Age-related and other hearing loss	66.0	0.1	61.3	72.8	64.1	0.1	59.0	70.9	71.3	0.0	67.4	76.6	71.0	0.0	66.8	77.1	71.0	0.0	67.6	75.9	76.3	0.0	73.2	80.7
Age-related macular degeneration	69.2	0.0	65.4	73.4	68.0	0.0	64.2	72.4	72.9	0.0	69.5	77.0	73.3	0.0	70.0	77.5	72.8	0.0	69.8	76.7	76.9	0.0	74.3	80.6
Alcohol use disorders	59.9	0.1	54.3	67.0	56.9	0.1	50.5	64.5	66.0	0.0	61.5	72.1	62.4	0.1	56.0	70.4	62.5	0.0	56.8	70.0	68.4	0.0	63.5	75.0
Alcoholic cardiomyopathy	54.4	4.0	42.2	67.4	42.3	16.6	26.6	57.4	60.2	1.5	55.1	69.0	59.6	2.7	51.3	71.2	62.2	1.4	56.3	71.7	71.2	0.7	67.9	77.4
Alopecia areata	63.1	0.3	57.7	70.7	60.5	0.3	54.4	68.3	68.8	0.0	64.3	74.7	67.6	0.1	62.4	74.9	67.7	0.0	63.5	74.0	73.2	0.0	69.8	78.7
Alzheimer's disease and other dementias	70.2	0.0	66.9	74.3	68.6	0.0	65.1	73.0	72.7	0.0	69.5	76.8	73.5	0.0	70.4	77.6	72.4	0.0	69.3	76.3	76.6	0.0	74.0	80.1
Amphetamine use disorders	55.9	0.2	50.4	63.4	54.3	0.2	48.0	62.0	61.9	0.1	57.3	68.2	59.7	0.4	53.7	67.7	57.4	0.3	49.3	66.7	67.5	0.0	63.7	73.2
Anorexia nervosa	58.0	0.6	51.9	66.1	55.2	0.7	48.3	63.8	63.8	0.1	58.8	70.6	62.0	0.5	56.2	70.5	61.7	0.3	56.7	69.3	67.2	0.2	63.4	74.2
Anxiety disorders	63.5	0.6	57.9	71.4	60.7	0.5	53.9	68.7	69.5	0.1	64.8	75.3	68.0	0.2	62.0	75.4	67.6	0.1	62.6	74.8	73.5	0.0	70.1	79.1
Appendicitis	61.6	3.8	56.4	71.5	55.0	7.1	47.4	68.0	69.4	0.2	64.9	75.3	66.1	1.7	60.5	75.5	67.2	0.4	62.6	74.4	73.1	0.1	69.2	79.1
Asbestosis	57.8	0.2	52.6	63.7	57.4	2.1	51.3	65.2	67.7	0.1	63.8	73.3	63.1	0.1	57.8	69.8	68.2	0.0	64.9	72.1	70.9	0.0	67.1	75.2
Asthma	59.1	1.8	53.2	67.9	56.0	2.0	49.3	65.3	67.2	0.4	62.9	73.6	65.0	0.8	59.7	73.2	66.0	0.4	61.8	73.1	72.5	0.1	69.2	78.3
Atopic dermatitis	63.0	1.6	57.4	71.6	60.0	1.6	53.3	68.9	69.7	0.2	65.0	75.4	67.9	0.5	62.2	75.6	68.3	0.2	64.2	74.6	74.1	0.1	70.8	79.3
Atrial fibrillation and flutter	68.2	0.0	64.5	73.0	65.3	0.0	61.0	70.6	71.6	0.0	68.1	75.9	70.7	0.0	66.9	75.8	71.2	0.0	68.1	75.2	73.6	0.0	70.6	77.9
Attention-deficit/hyperactivity disorder	62.1	1.7	56.9	71.0	58.8	1.9	52.9	68.3	67.9	0.5	63.0	74.8	66.3	0.9	60.9	74.9	66.0	0.5	61.5	73.8	72.1	0.2	68.0	78.5
Autism spectrum disorders	50.5	7.5	46.1	60.5	47.5	8.6	42.7	58.2	57.7	1.6	54.0	63.6	56.2	2.8	51.6	64.5	56.5	1.5	52.2	63.7	61.9	0.6	58.4	67.6
Benign and in situ cervical and uterine neoplasms	64.3	0.3	58.3	71.8	62.0	0.1	55.1	69.1	69.7	0.0	64.4	75.6	69.1	0.0	63.2	75.8	67.5	0.0	62.2	74.7	73.4	0.0	69.5	79.4

Benign and in situ intestinal neoplasms	67.1	0.2	62.3	73.2	63.0	0.9	57.6	70.5	71.5	0.0	67.6	76.3	70.5	0.3	65.5	77.2	70.1	0.0	65.8	75.3	75.3	0.0	71.7	80.1
Benign prostatic hyperplasia	68.0	0.0	63.4	73.3	65.5	0.0	60.7	71.1	72.1	0.0	68.3	76.7	71.0	0.0	66.6	76.7	70.7	0.0	67.0	75.4	75.0	0.0	71.7	79.7
Bipolar disorder	55.8	0.6	50.8	62.4	53.5	0.7	48.1	60.6	64.1	0.1	59.6	69.8	60.0	0.4	55.2	66.8	61.1	0.2	56.6	67.2	67.0	0.1	62.8	72.6
Bladder cancer	64.2	0.1	59.1	70.6	63.1	0.0	57.9	69.3	70.3	0.0	66.4	75.3	69.5	0.0	64.7	75.7	70.4	0.0	66.5	75.2	75.5	0.0	72.2	80.0
Brain and nervous system cancer	35.4	38.2	9.8	58.2	39.2	26.7	15.4	57.4	62.5	2.3	56.1	72.4	49.9	13.0	37.5	65.5	60.8	1.5	54.0	70.3	71.9	0.7	68.3	79.1
Breast cancer	60.1	0.1	50.9	69.7	59.3	0.0	51.6	68.0	69.1	0.0	64.1	75.3	68.2	0.0	62.3	75.5	69.8	0.0	65.6	75.6	74.2	0.0	70.7	80.0
Bulimia nervosa	58.3	0.5	52.3	66.4	55.3	0.5	48.5	63.9	63.8	0.1	59.0	70.6	62.2	0.3	56.5	70.6	62.0	0.2	57.1	69.5	67.9	0.1	64.1	74.3
Cannabis use disorders	62.4	0.4	57.0	70.3	59.3	0.6	53.1	67.7	67.9	0.1	63.3	74.3	66.6	0.2	61.3	74.6	65.8	0.2	61.0	73.1	71.8	0.1	68.1	78.0
Caries of deciduous teeth	62.8	1.6	56.7	71.8	59.4	1.9	52.7	69.1	68.6	0.5	63.7	75.6	67.0	0.9	61.6	75.8	66.8	0.5	61.4	74.7	72.9	0.2	68.7	79.4
Caries of permanent teeth	64.1	0.3	58.3	71.8	61.2	0.4	54.3	69.1	69.7	0.0	64.4	75.6	68.4	0.2	62.4	75.8	68.1	0.1	63.6	75.2	73.8	0.0	70.2	79.4
Cataract	68.1	0.0	64.0	73.4	67.8	0.0	63.8	72.9	73.8	0.0	70.7	77.9	73.8	0.0	70.6	78.3	73.4	0.0	70.6	77.6	77.7	0.0	75.2	81.2
Cellulitis	64.0	0.9	58.3	71.7	60.9	1.3	54.3	69.0	70.1	0.2	65.2	76.2	68.7	0.4	63.1	76.4	69.6	0.1	65.1	75.3	74.5	0.1	70.9	80.0
Cervical cancer	59.9	0.1	51.5	69.3	57.3	0.1	48.4	66.5	65.5	0.0	58.7	73.8	64.4	0.0	55.8	74.1	65.5	0.0	59.6	73.0	71.6	0.0	67.6	78.6
Chronic kidney disease due to diabetes mellitus type 1	47.2	3.0	38.9	56.8	36.1	4.4	30.4	41.4	49.4	0.9	40.9	59.0	36.9	3.3	30.2	42.1	62.7	0.1	58.3	69.0	69.1	0.0	65.9	74.0
Chronic kidney disease due to diabetes mellitus type 2	67.3	0.1	62.9	72.9	65.3	0.0	60.7	70.9	72.0	0.0	68.2	76.6	69.8	0.0	65.2	75.5	70.9	0.0	67.5	75.2	75.6	0.0	72.5	79.6
Chronic kidney disease due to glomerulonephritis	64.4	1.6	59.9	72.4	62.2	1.1	56.7	70.3	71.6	0.1	67.7	76.9	67.0	0.3	60.8	74.9	71.4	0.0	68.2	75.9	76.5	0.0	73.8	80.7
Chronic kidney disease due to hypertension	57.2	0.9	51.5	64.8	54.1	1.0	47.9	61.8	62.9	0.2	58.0	69.6	58.0	0.4	52.0	65.4	62.1	0.1	56.7	69.1	69.9	0.0	66.4	75.3
Chronic kidney disease due to other and unspecified causes	66.1	0.7	61.5	73.0	64.2	0.9	59.7	71.1	72.3	0.1	68.3	77.0	70.8	0.2	66.3	77.0	71.6	0.0	67.9	75.9	76.6	0.0	73.2	80.7
Chronic lymphoid leukemia	63.3	0.3	58.3	69.8	61.7	0.4	56.6	68.5	68.4	0.2	63.3	75.1	68.5	0.2	63.5	75.2	69.8	0.0	65.7	75.1	74.9	0.0	71.7	80.1
Chronic myeloid leukemia	47.8	4.7	32.7	62.1	49.9	1.6	38.4	61.0	64.0	0.4	57.9	72.9	58.7	0.9	48.8	70.4	63.5	0.2	57.3	72.2	70.8	0.1	66.7	77.9
Chronic obstructive pulmonary disease	61.2	0.4	55.9	68.0	62.4	0.2	57.2	69.0	69.2	0.0	65.1	74.3	69.7	0.1	65.3	75.7	68.0	0.0	64.1	73.0	74.9	0.0	71.5	79.7
Cirrhosis and other chronic liver diseases due to alcohol use	57.3	0.0	50.8	64.3	56.1	0.0	49.3	62.8	67.4	0.0	62.4	74.3	63.3	0.0	56.5	71.1	61.5	0.0	54.3	69.2	70.8	0.0	66.4	77.2
Cirrhosis and other chronic liver diseases due to hepatitis B	64.6	0.0	58.3	71.8	60.5	0.0	53.5	68.3	69.3	0.0	64.4	75.5	68.1	0.0	62.4	75.7	68.7	0.0	64.3	74.6	73.7	0.0	70.2	79.4
Cirrhosis and other chronic liver diseases due to hepatitis C	62.1	0.1	55.0	70.2	59.4	0.0	51.9	67.5	68.9	0.0	63.6	75.4	63.3	0.0	55.7	71.9	66.4	0.0	60.5	73.6	71.9	0.0	67.4	78.6
Cirrhosis and other chronic liver diseases due to other causes	53.7	3.9	47.1	64.0	52.9	4.5	46.5	63.1	65.8	0.9	60.9	73.7	61.2	1.4	54.7	71.0	60.8	0.4	53.2	70.1	69.9	0.3	65.3	76.9
Cocaine use disorders	52.0	0.6	42.8	61.7	53.7	0.7	47.5	62.0	60.9	0.1	56.2	68.3	60.4	0.5	55.1	68.1	57.5	0.5	50.3	66.5	65.8	0.1	62.4	71.6
Colon and rectum cancer	59.6	0.3	53.0	68.8	59.0	0.2	52.6	66.8	68.9	0.0	64.3	74.7	67.7	0.1	62.2	75.1	69.2	0.0	64.9	75.2	74.6	0.0	70.8	79.9
Conduct disorder	61.6	1.2	56.0	70.3	58.3	1.4	51.9	67.6	67.1	0.4	62.4	74.0	65.6	0.9	60.0	74.3	65.3	0.5	60.7	73.2	71.4	0.2	67.8	78.0
Conflict and	65.2	0.1	59.8	71.8	62.3	0.1	55.9	69.7	70.2	0.0	65.2	75.6	69.6	0.0	64.0	76.4	68.7	0.0	63.6	74.6	74.1	0.1	70.2	79.4









Orofacial clefts	55.8	10.3	51.9	69.1	53.5	10.3	47.7	67.2	65.9	1.9	62.0	73.0	64.2	2.8	59.2	73.9	64.9	1.3	60.1	73.1	71.2	0.5	67.2	77.7
Osteoarthritis	66.4	0.0	61.6	72.4	64.1	0.0	58.9	70.1	70.0	0.0	65.6	75.4	70.2	0.0	65.7	76.3	69.7	0.0	65.6	75.0	74.5	0.0	71.1	79.5
Other benign and in situ neoplasms	65.1	0.9	59.9	72.5	62.6	1.0	56.8	70.5	70.6	0.1	66.0	76.3	69.9	0.4	64.8	76.5	70.1	0.0	65.8	75.3	74.8	0.1	71.0	80.1
Other cardiomyopathy	49.8	6.4	34.7	65.9	40.4	13.0	26.0	55.6	60.8	2.3	56.2	69.8	57.5	3.8	48.0	70.6	59.7	2.7	52.9	71.0	70.7	0.8	67.4	77.5
Other cardiovascular and circulatory diseases	63.0	0.5	57.2	71.3	61.8	0.3	56.4	69.5	70.6	0.0	67.0	75.3	70.3	0.0	66.3	76.1	70.5	0.0	67.4	75.2	75.5	0.0	72.8	79.7
Other chromosomal abnormalities	52.6	9.8	48.5	64.9	36.0	34.6	0.5	58.9	59.9	4.6	55.8	68.5	52.9	13.1	46.2	68.2	14.8	75.6	0.0	13.2	62.8	6.8	60.6	73.0
Other congenital birth defects	41.0	23.3	26.7	57.8	5.0	90.9	0.0	0.4	55.6	9.7	53.6	66.8	31.1	46.7	0.4	60.8	43.0	23.0	25.2	60.9	50.5	14.5	49.1	63.9
Other exposure to mechanical forces	63.4	1.5	57.5	71.7	60.9	1.0	54.3	69.1	69.6	0.2	64.4	75.6	68.6	0.3	63.2	76.4	68.3	0.1	63.6	74.6	74.2	0.0	71.0	79.4
Other gynecological diseases	63.7	0.1	57.9	71.5	60.8	0.1	54.1	68.8	69.1	0.0	64.2	75.3	68.2	0.0	62.8	75.7	67.3	0.0	62.5	74.4	73.0	0.0	69.3	79.2
Other hemoglobinopathies and hemolytic anemias	80.9	0.0	80.2	81.5	80.6	0.0	79.8	81.1	83.2	0.0	82.3	84.0	82.6	0.0	81.6	83.3	79.6	0.0	78.9	80.2	82.8	0.0	81.9	83.1
Other leukemia	41.3	33.8	11.7	65.6	49.2	14.8	37.4	65.0	62.5	5.0	57.6	73.9	55.6	10.8	42.8	72.0	66.5	1.1	62.5	73.9	71.3	0.5	67.1	77.9
Other malignant neoplasms	45.2	20.1	25.3	63.7	47.8	13.5	36.3	62.8	70.1	0.2	65.7	76.0	55.3	8.3	44.7	70.3	65.9	0.5	60.5	73.6	75.4	0.1	72.2	80.4
Other oral disorders	63.6	1.0	57.5	71.8	60.8	0.9	54.3	69.1	69.6	0.1	64.4	75.6	68.2	0.4	62.4	75.8	67.9	0.2	62.9	74.6	73.7	0.0	70.2	79.4
Other pharynx cancer	53.0	1.1	45.8	61.2	54.7	0.4	48.4	61.5	62.6	0.1	56.1	70.5	59.8	0.3	53.1	67.0	66.7	0.0	61.2	73.1	68.3	0.0	62.7	74.8
Other pneumoconiosis	59.8	0.6	54.2	67.0	59.9	0.9	54.2	69.1	66.9	0.1	62.7	73.2	68.6	0.2	64.7	74.6	66.6	0.1	62.5	72.4	71.9	0.0	68.5	76.3
Other road injuries	64.2	0.6	58.3	71.7	61.2	1.4	55.1	69.7	69.8	0.1	65.2	75.6	69.0	0.4	63.9	76.4	68.6	0.3	64.4	75.3	74.8	0.0	71.7	80.0
Other skin and subcutaneous diseases	65.0	0.7	59.1	72.5	62.8	0.6	56.8	69.8	71.1	0.0	66.8	76.3	70.1	0.2	65.5	76.5	70.2	0.0	65.8	75.3	75.7	0.0	72.5	80.1
Other transport injuries	63.7	1.3	58.3	71.7	55.9	8.9	51.0	69.0	70.2	0.2	65.2	76.3	68.5	1.3	63.9	76.4	69.4	0.2	65.1	75.3	75.6	0.0	72.4	80.7
Other unintentional injuries	63.7	1.3	58.3	71.7	60.9	1.8	55.1	69.7	70.1	0.2	65.2	75.6	69.1	0.4	63.9	76.4	69.3	0.1	65.1	75.3	74.7	0.0	71.0	80.0
Other vision loss	63.2	0.4	58.4	69.8	61.9	0.2	56.7	68.7	70.8	0.0	67.0	75.8	68.9	0.1	64.6	75.1	70.0	0.0	66.4	75.3	75.7	0.0	72.9	80.1
Ovarian cancer	58.1	0.5	50.4	67.5	56.7	0.3	49.0	65.3	63.6	0.0	56.7	71.5	62.8	0.2	54.5	72.5	64.8	0.0	58.6	71.9	69.9	0.0	63.8	77.9
Pancreatic cancer	57.5	0.4	50.9	65.2	55.8	0.2	49.3	62.9	60.8	0.0	54.5	67.4	59.7	0.1	52.4	67.0	62.1	0.0	55.8	68.6	67.9	0.0	62.1	74.5
Pancreatitis	64.9	0.4	59.1	72.4	63.2	0.2	57.5	70.5	71.0	0.0	66.7	76.3	69.9	0.1	64.7	77.1	70.0	0.0	65.8	75.3	75.0	0.0	71.7	80.0
Paralytic ileus and intestinal obstruction	36.1	31.7	14.5	56.6	34.1	37.4	4.1	57.4	63.0	4.7	59.3	73.2	49.2	16.7	35.0	68.5	68.0	0.7	64.2	74.4	69.4	0.4	63.8	76.4
Parkinson's disease	67.0	0.0	63.3	71.7	64.9	0.0	61.1	69.7	69.5	0.0	65.9	74.0	69.9	0.0	66.5	74.4	69.0	0.0	65.8	73.0	73.1	0.0	70.0	77.1
Pedestrian road injuries	63.4	2.2	58.3	71.7	55.3	11.2	49.3	69.0	69.5	0.7	65.2	75.6	67.3	2.5	63.1	76.4	68.2	0.5	64.3	75.2	74.8	0.2	71.7	80.0
Peptic ulcer disease	64.9	0.3	59.0	72.3	63.1	0.3	57.4	70.5	70.9	0.0	66.7	76.2	71.8	0.1	67.7	78.3	70.8	0.0	67.2	75.8	75.6	0.0	72.3	80.6
Periodontal diseases	65.8	0.0	59.9	72.5	62.8	0.0	56.8	69.8	70.9	0.0	66.0	76.3	69.6	0.0	64.0	76.5	70.0	0.0	65.8	75.3	75.3	0.0	71.7	80.0
Peripheral artery disease	68.6	0.0	63.8	73.7	66.6	0.0	61.5	71.8	72.1	0.0	68.2	76.9	72.2	0.0	67.8	77.1	71.4	0.0	67.9	75.9	76.3	0.0	73.1	80.6
Physical violence by firearm	58.5	7.0	53.4	71.1	40.6	20.9	20.8	62.2	69.6	0.4	65.2	76.2	50.8	12.6	24.2	73.0	64.2	3.4	59.9	74.6	74.0	0.1	70.2	79.4
Physical violence by other means	63.4	1.5	57.5	71.7	57.3	6.4	51.8	69.0	69.6	0.2	64.4	75.6	63.7	4.5	57.5	75.8	67.5	0.4	62.9	75.2	73.6	0.2	70.2	79.4
Physical violence by sharp object	63.7	1.0	58.3	71.8	58.6	2.9	52.7	69.0	69.3	0.2	64.4	75.6	67.3	1.1	61.6	75.8	67.4	0.2	62.2	74.6	73.6	0.1	70.2	79.4
Poisoning by carbon monoxide	61.3	4.4	56.6	71.7	48.6	20.1	35.7	67.5	66.0	3.4	62.8	75.5	62.1	9.2	58.3	75.7	66.9	1.3	62.8	74.6	73.8	0.2	70.2	79.9
Poisoning by other means	59.5	6.9	55.0	71.6	53.0	13.0	46.8	67.5	68.0	1.7	64.3	75.5	65.1	4.0	59.9	75.7	68.2	0.7	64.3	75.2	74.1	0.1	70.9	79.9
Polycystic ovarian syndrome	63.4	0.4	58.0	71.5	60.1	0.7	53.2	68.8	69.1	0.1	64.2	75.5	67.4	0.3	62.1	75.6	67.4	0.2	62.6	74.6	73.0	0.1	69.2	79.1
Premenstrual syndrome	64.0	0.2	58.3	71.8	61.0	0.2	54.3	69.1	69.3	0.0	64.4	75.6	68.2	0.1	62.4	75.8	67.6	0.1	62.2	74.6	73.3	0.0	69.5	79.4
Prostate cancer	66.2	0.0	62.1	70.8	65.7	0.0	61.5	70.5	71.9	0.0	68.2	76.0	72.1	0.0	68.3	76.9	71.2	0.0	67.0	75.6	76.1	0.0	72.9	80.3
Pruritus	64.5	0.7	59.1	72.5	62.1	0.6	55.9	69.8	70.7	0.1	66.0	76.3	69.5	0.2	64.0	76.5	69.6	0.1	65.1	75.3	75.3	0.0	71.7	80.0
Psoriasis	61.1	0.5	56.0	68.4	59.1	0.5	53.5	66.5	67.8	0.0	63.6	73.4	66.1	0.2	61.3	73.1	65.9	0.1	61.8	72.1	71.9	0.0	68.4	77.1
Pulmonary aspiration	53.2	16.9	46.7	70.3	25.2	60.9	0.5	59.1	67.4	3.1	63.6	75.6	36.5	43.6	3.4	67.8	67.2	4.6	65.1	75.8	74.7	1.6	72.4	80.7




## 1    **References**

- 2    1.    GBD Causes of Death Collaborators, *Global, regional, and national age-sex-specific mortality*  
3        *for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for*  
4        *the Global Burden of Disease Study 2017*. *Lancet*, 2018. **392**(10159): p. 1736-1788.
- 5    2.    Das Gupta, P., *Standardization and Decomposition of Rates: A User's Manual*. U.S.  
6        *Department of Commerce, Economics and Statistics Administration*, B.o.t. Census, Editor.  
7        1993.


# Age at death for total population in United States





## iLE for Acute myeloid leukemia in United States



## iLE for Acute lymphoid leukemia in United States




# Examples of iHALE Calculation at Individual Level







## Acute myeloid leukemia in United States




## Acute lymphoid leukemia in United States




**Incidence rate for Acute lymphoid leukemia in United States**




**Incidence rate for Acute myeloid leukemia in United States**



**Incidence for Acute lymphoid leukemia in United States**



**Incidence for Acute myeloid leukemia in United States**



# Difference in Average iHALE between Japan and Ethiopia, Decomposed into Factors Driving Differences

